Fresenius Medical Care AG & Co. KGaA (FMS)
| Previous close | 35.35 |
| Open | 35.52 |
| Bid | 35.49 x 900 |
| Ask | 35.51 x 1000 |
| Day's range | 35.27 - 35.63 |
| 52-week range | 33.84 - 44.13 |
| Volume | 267,294 |
| Avg. volume | 319,017 |
| Market cap | 21.105B |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | 15.43 |
| EPS (TTM) | 2.30 |
| Earnings date | N/A |
| Forward dividend & yield | 0.82 (1.97%) |
| Ex-dividend date | 24 May 2021 |
| 1y target est | 40.82 |
- Business Wire
Fresenius Medical Care Partners with JMS Co. Ltd. to Advance Home Dialysis Treatment in Japan
HONG KONG, September 17, 2021--Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, has today announced a strategic distribution partnership with JMS Co. Ltd, a provider of medical devices and pharmaceuticals, in Japan. Under the agreement, JMS Co. Ltd. will distribute Fresenius Medical Care’s innovative home dialysis therapies in the Japanese market, providing patients with a wider range of dialysis choices to suit their lifestyle, e
- Zacks
Fresenius Medical (FMS) Q2 Earnings Beat Estimates, Up Y/Y
Fresenius Medical's (FMS) second-quarter earnings benefit from strong performance across the regions, EMEA, Asia Pacific and Latin America.
- EQS Group
Fresenius Medical Care AG & Co. KGaA reports results in line with expectations for the second quarter and confirms 2021 outlook
DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Half Year Results30.07.2021 / 07:03 The issuer is solely responsible for the content of this announcement. As assumed, COVID-19 pandemic continued to impact organic growth in dialysis and downstream businesses Patient excess mortality rates significantly reduced Negative exchange rate effects continue Earnings development impacted by phasing and strong prior-year base, as indicated Financial targets for FY 2021 confirmed FME25 progra
